

Nanoparticulate Formulation for the Treatment of Different Types of Colon Disease Like Ulcerative Colitis: A Comprehensive Review

Debgopal Ganguly¹, Ananta Choudhury^{1,*}, Ranabir Chanda², Hira Das², Sumit Mitra², Riya Ghosh², Deblina Sardar³

¹Faculty of Pharmaceutical Science, Assam Down Town University, Sankar Madhab Path Gandhi Nagar, Panikhaiti, Guwahati, Assam, INDIA.

²School of Pharmacy, Seacom Skills University, Bolpur, Birbhum, West Bengal, INDIA.

³Eminent College Of Pharmaceutical Technology, Barasat, Jagannathpur, West Bengal, INDIA.

ABSTRACT

It is crucial to use a colon-targeted medication delivery system to treat diseases that start in the colon, such as inflammatory bowel disease, colon cancer, amoebiasis, and irritable bowel syndrome. Through colon targeted drug delivery system, we can give localised treatment to the patient which reduces the chance of toxicity and improves its therapeutic efficacy. The bioavailability of medications for the colon has greatly increased because to recent improvements in oral formulations. But because it is intimately linked to GI Inflammation, it is crucial to make some changes to the Gastrointestinal (GI) physiology to increase the therapeutic effect even more. Due to their structural makeup and smaller size, nanoparticles are often used in the administration of drugs that are specifically targeted for the colon. It is designed in such a way that it promotes aggregation time of drugs at the site of action, supporting localized therapy. This review article mainly focuses on oral nanoparticulate formulations that are targeted for treating Colon related diseases.

Keywords: Colon, Ulcerative Colitis, Nanoparticles, Drug delivery, Formulations.

Correspondence:

Dr. Ananta Choudhury

Faculty of Pharmaceutical Science,
Assam Down Town University, Sankar
Madhab Path Gandhi Nagar, Panikhaiti,
Guwahati-781026, Assam, INDIA.
Email: anantachoudhury@gmail.com

Received: 28-05-2023;

Revised: 10-07-2023;

Accepted: 28-07-2023.

INTRODUCTION

Nanotechnology is regarded as the most important area of study in the twenty-first century. These so-called nanoparticles are actually very tiny colloidal particles, which have a diameter of about 200 nm and can be either biodegradable or non-biodegradable polymers. It is much more advanced over conventional dosage forms as the formulated drug increases efficacy, improves biodistribution as well as patient compliance, also reducing the toxicity risk. In nanoparticulate formulations the main drug is dissolved, entrapped and encapsulated to nanoparticles matrices. In the digestion process the colonic colonies plays a very important role and it is the site of decomposition of the macromolecule polysaccharides which are difficult to digest.

In these recent days, we can see that oral routed medicines are mostly preferred for treatment of colon diseases. Although it is very difficult to administer polypeptide drugs as because it is

endangered by gastric acid or secretory protease degradation resulting in inactivation of the drug in the digestive tract. But oral route is not preferred at the time of emergency as it has slow absorption rate.^{1,2}

Ulcerative Colitis

Widespread colonic mucosal inflammation is a hallmark of ulcerative colitis (UC), a kind of inflammatory bowel disease. It affects the rectum and lasts however long it does proximally along the colon. There are two main kinds of the condition (inflammation beyond the splenic flexure): left sided colitis, which produces inflammation up to the splenic flexure, and extensive colitis. When choosing a course of therapy and planning surveillance colonoscopies, which are used to find and treat colorectal cancer, these classifications are important. One in a thousand people in the Western world have colitis.³

Causes of ulcerative colitis

Inflammatory bowel disease may arise from environmental factors even though its precise cause is unknown in genetically predisposed people. Most likely, an inflammatory response to gut bacteria causes the autoimmune condition ulcerative colitis. An inflammatory bowel disease (crohn's disease or ulcerative



DOI: 10.5530/jyp.2023.15.82

Copyright Information :

Copyright Author (s) 2023 Distributed under
Creative Commons CC-BY 4.0

Publishing Partner : EManuscript Tech. [www.emanuscript.in]

colitis) affects 10% to 20% of persons with this condition. Some inflammatory bowel disease patients may experience a flare-up of their condition after taking non-steroidal anti-inflammatory medications. Paracetamol is probably a safer option for analgesia, even though modest non-steroidal anti-inflammatory medicines like ibuprofen may occasionally be administered if patients are informed of the potential for a higher risk of recurrence. Compared to Crohn's disease, ulcerative colitis is less likely to be brought on by smoking. Colitis coexists with gastroenteritis caused by known infections in up to 50% of cases.

Symptoms in patients suffering from ulcerative colitis

A brief history, assessment of endoscopic and radiological appearances, microbiology and histology is required for the diagnosis of colitis. Cardinal symptoms of UC are as follows:

- i. Urgency,
- ii. Tenesmus (Straining at stool),
- iii. Bloody diarrhoea.

Even in individuals who have experienced a known relapse of ulcerative colitis, stool cultures should be taken (especially for *Clostridium difficile* toxin). Endoscopy should be done if bloody diarrhoea persists for longer than three weeks since it may indicate the existence of inflammatory bowel disease.⁴

Diagnosis of ulcerative colitis

The diagnosis of ulcerative colitis requires both an endoscopy and a mucosal biopsy. Despite the distinctions, there is a significant amount of similarity between the endoscopic findings of Crohn's disease and ulcerative colitis. Except for the typical patch of inflammation around the appendix's base, the rectum is continuously and uniformly afflicted, and the colon develops ulcers. In Crohn's disease, the terminal ileum frequently becomes ulcerated, while the rectum frequently remains unaffected and other parts of the colon frequently remain whole. It may be challenging to identify between isolated colonic Crohn's disease and ulcerative colitis in roughly one-third of instances of colitis; these patients are referred to as having indeterminate colitis.⁵

Nanoparticles for Colon Targeting

Any particulate material with at least one dimension between 1 and 100 nm is referred to as a Nanoparticle (NP). The method employed for a nanoparticle's creation has a significant impact on its size. The only type of medication delivery device that can get past all physiological barriers and function at a specific target spot is a nanoparticle. Except being a drug carrier or a dissolving or an encapsulating form of drug, nanoparticles can also be used by adsorbing or attaching the active substances. There are evidences where nanoparticles have shown improved efficacy, less toxicity and a huge enhancement of biodistribution if compared

with conventional dosage forms. Drug delivery systems that are based on nanoparticles, have proven to be pharmacokinetically and pharmacodynamically more advanced.^{6,7} Because of their biodegradability, ion and temperature sensitivity, as well as pH levels, they also demonstrated controlled release capabilities. The drug rate of drug release can be interfered by polymer degradation process. Because they avoid any difficulties brought on by the long-term deposition of nanoparticles or any remaining components inside the ulcerated tissue, biodegradable polymers are employed to create nanoparticles.^{8,9}

However, dose deterioration resulted to the release of the entrapped drug, so to address this issue, drug-filled nanoparticles were sealed within pH-sensitive microspheres. This allowed the nanoparticles to act right where they were needed, which immediately stopped the drug leakage. In contrast to their bulk counterparts, Nanoparticles (NPs) have a variety of characteristics, including as high surface energy and unusual mechanical, thermal, and optical behaviours. By adding various functional groups to the surface of NPs, one can vary their chemical activity and dispersibility, making them ideal for use in specific environments. Thus, by using a variety of techniques, we may conclude that nanoparticles may be a very effective instrument for targeted medication delivery at particular locations within the inflamed colon.^{10,11}

Nanoparticulate Formulation as a Drug Delivery Techniques for Ulcerative Colitis

Nanoparticles use a number of targeting strategies to cross the epithelial barrier and into the UC site. This method of administering drugs allows for the delivery of high local drug concentrations, reduced drug degradation and efficacy loss before to site of action, and a reduction in systemic medication adverse effects.^{12,13}

Nanoparticulate formulation as Drug delivery techniques for UC

- Depending on the pH of the location following ingestion, nanoparticles target the epithelium of the inflammatory colon.
- Targets the inflamed colon epithelium based on the level of Reactive Oxygen Species (ROS) there.
- Used to deliver nanoparticles to the inflamed colon after oral treatment.
- Directed at the inflamed colonic epithelium via a ligand-receptor interaction. (Oral therapy).^{14,15}

Nanoparticles used for Colonic Ulcerative colitis

Artificial nanoparticles have proved effective in treating Ulcerative Colitis (UC) in the pre-clinical stage. Despite its popularity, it has two shortcomings. Each of these nanoparticles' potential toxicities

must be assessed before clinical procedures. The product's scale is also limited.^{16,17} Contrarily, it is believed that nanoparticles obtained from natural sources are inexpensive, risk-free, and may be able to get around the limitations of synthetic nanoparticles. Extracellular Vesicles (EVs) protected from mammalian cells and factory-derived nanoparticles have recently demonstrated significant preclinical potential for the treatment of UC. These findings suggest that naturally occurring nanoparticles might offer a cutting-edge UC treatment approach.^{18,19}

Plant-Derived Nanoparticles

Finding out whether artificially produced nanoparticles can contribute to interspecies communication and have a direct beneficial impact on fatal illnesses, particularly intestinal inflammation, is of great interest.^{20,21} Grape Nanoparticles (GELNs) that are ingested orally and contain proteins, lipids, and micro-RNA are designed to pass through the gut and be absorbed by intestinal stem cells. Similar to how they were resistant to degradation by slaver, the stomach's acidic environment, and the intestinal tract's abundantly active proteolytic enzymes.^{22,23} These results suggested that edible factory-ground nanoparticles might be taken up by intestinal cells and supplied orally to the intestine, where they might provide conditioning akin to intestinal rejuvenescence. Combustible factory-produced nanoparticles with anti-inflammatory properties that naturally target the colon may thus constitute a novel natural delivery method that could effectively be used to treat patients with digestive tract diseases like IBD.^{24,25}

pH-dependent Nano-delivery Systems

Methacrylic acid copolymers (Eudragit) are the pH-dependent coating polymers most frequently utilised for oral administration. The pH at which the side chains become soluble can change depending on how they are made. For instance, pH-sensitive nanoparticles containing the topically active corticosteroid Budesonide (BSD) (Eudragit S100) were produced using poly- (lactic-co-glycolic acid) and methacrylate copolymer combinations. At both acidic and neutral pH levels, these nanospheres showed strong drug release properties that were pH dependent, with a sustained release phase occurring at pH 7.4.^{26,27} Studies on animals utilising a TNBS-induced colitis model revealed that BSD-loaded nanospheres were superior to BSD alone as a therapeutic agent. These nanospheres showed *in vivo* stronger and more targeted adhesion to ulcerated and inflamed rat mucosal colonic tissue than conventional enteric-coated microparticles.^{28,29} Additionally, their systemic toxicity was reduced.

There are still numerous reasons for caution despite the promising results of these pH-dependent nano-delivery systems for the colon. These consist of both the typical intra- and inter-individual pH variations and alterations in luminal pH brought on by diseases. Therefore, for improved disease therapy,

researchers should consider the individual inflammation status while devising a delivery system to target the colon based only on pH.^{30,31}

ROS-responsive Nano Delivery Systems

Drug carriers that respond to changes in redox potential may also show clinical benefit in the treatment of UC. Reactive Oxygen Species (ROS) production is out of balance, and antioxidant defence mechanisms deteriorate under oxidative stress. Due to the considerable ROS production by inflammatory cells like neutrophils and macrophages, oxidative stress is a hallmark of inflammatory processes. ROS overproduction has been linked to UC.^{32,33} For instance, in biopsies collected from the sites of people with UC compared to those without the disease, mucosal ROS concentrations are 10- to 100-fold higher, and ROS concentrations are linked with disease development. By leveraging the pathological characteristics of the disease, redox-responsive nano-delivery technologies provide significant potential for IBD therapy.³⁴⁻⁴⁰

CONCLUSION

We have primarily concentrated on the benefits of nanotechnology for treating ulcerative colitis in this review study. However, nanotechnological approaches may be used to treat Crohn's disease by administering drug-loaded nanoparticles to both the large intestine and the small intestine (another source of this disease). Targeting and maintaining nanoparticle-loaded drugs in the small intestine present two challenges due to the need to specifically release nanoparticles from the hydrogel to this organ and/or decorate the nanoparticles with ligands specific to receptors expressed mostly in epithelial cells of the small intestine.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle drug delivery technologies for oral delivery applications. *Expert Opin Drug Deliv*. 2015;12(9):1459-73. doi: 10.1517/17425247.2015.1018175, PMID 25813361.
2. Li DF, Yang MF, Xu HM, Zhu MZ, Zhang Y, Tian CM, *et al.* Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease. *J Mater Chem B*. 2022;10(31):5853-72. doi: 10.1039/d2tb01190e, PMID 35876136.
3. Mondal S, Das M, Ghosh R, Singh M, Adhikari A, Darbar S, *et al.* Chitosan functionalized Mn3O4 nanoparticles counteracts ulcerative colitis in mice through modulation of cellular redox state. *Commun Biol*. 2023;6(1):647. doi: 10.1038/s42003-023-05023-6, PMID 37328528.
4. Lv F, Zhang Y, Peng Q, Zhao X, Hu D, Wen J, *et al.* Apigenin-Mn(II) loaded hyaluronic acid nanoparticles for ulcerative colitis therapy in mice. *Front Chem*. 2022;10:969962. doi: 10.3389/fchem.2022.969962, PMID 35936086.
5. Wu Y, Briley K, Tao X. Nanoparticle-based imaging of inflammatory bowel disease. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2016;8(2):300-15. doi: 10.1002/wnan.1357, PMID 26371464.
6. Borner MM, Schöffski P, De Wit R, Caponigro F, Comella G, Sulkes A, *et al.* Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. *Eur J Cancer*. 2002;38(3):349-58. doi: 10.1016/s0959-8049(01)00371-9, PMID 11818199.
7. Wachsmann P, Lamprecht A. Polymeric nanoparticles for the selective therapy of inflammatory bowel disease. *Meth Enzymol*. 2012;508:377-97. doi: 10.1016/B978-0-12-391860-4.00019-7, PMID 22449936.

8. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. *Adv Drug Deliv Rev.* 2012;64(6):557-70. doi: 10.1016/j.addr.2011.12.009, PMID 22212900.
9. Zhang M, Merlin D. Nanoparticle-based oral drug delivery systems targeting the colon for treatment of ulcerative colitis. *Inflam Bowel Dis.* 2018;24(7):1401-15. doi: 10.1093/ibd/izy123, PMID 29788186.
10. Sohail M, Mudassir MU, Minhas MU, Khan S, Hussain Z, de Matas M, *et al.* Natural and synthetic polymer-based smart biomaterials for management of ulcerative colitis: a review of recent developments and future prospects. *Drug Deliv Transl Res.* 2019;9(2):595-614. doi: 10.1007/s13346-018-0512-x, PMID 29611113.
11. Xiao B, Zhang Z, Viennois E, Kang Y, Zhang M, Han MK, *et al.* Combination therapy for ulcerative colitis: orally targeted nanoparticles prevent mucosal damage and relieve inflammation. *Theranostics.* 2016;6(12):2250-66. doi: 10.7150/thno.15710, PMID 27924161.
12. Nidhi M, Rashid M, Kaur V, Hallan SS, Sharma S, Mishra N. Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review. *Saudi Pharm J.* 2016;24(4):458-72. doi: 10.1016/j.jsps.2014.10.001, PMID 27330377.
13. Zhang J, Zhao Y, Hou T, Zeng H, Kalambhe D, Wang B, *et al.* Macrophage-based nanotherapeutic strategies in ulcerative colitis. *J Control Release.* 2020;320:363-80. doi: 10.1016/j.jconrel.2020.01.047, PMID 32001299.
14. Singh A, Kaur K, Mandal UK, Narang RK. Nanoparticles as budding trends in colon drug delivery for the management of ulcerative colitis. *Curr Nanomed.* 2020;10(3):225-47. doi: 10.2174/2468187310999200621200615.
15. Schmidt C, Lautenschlaeger C, Collnot EM, Schumann M, Bojarski C, Schulzke JD, *et al.* Nano-and microscaled particles for drug targeting to inflamed intestinal mucosa-A first *in vivo* study in human patients. *J Control Release.* 2013;165(2):139-45. doi: 10.1016/j.jconrel.2012.10.019, PMID 23127508.
16. Naeem M, Lee J, Oshi MA, Cao J, Hlaing SP, Im E, *et al.* Colitis-targeted hybrid nanoparticles-in-microparticles system for the treatment of ulcerative colitis. *Acta Biomater.* 2020;116:368-82. doi: 10.1016/j.actbio.2020.09.017, PMID 32937207.
17. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles-based drug delivery systems. *Colloids Surf B Biointerfaces.* 2010;75(1):1-18. doi: 10.1016/j.colsurf.2009.09.001, PMID 19782542.
18. Anwer MK, Ahmed MM, Aldawsari MF, Alshahrani S, Fatima F, Ansari MN, *et al.* Eluxadolone loaded solid lipid nanoparticles for improved colon targeting in rat model of ulcerative colitis. *Pharmaceuticals (Basel).* 2020;13(9):255. doi: 10.3390/ph13090255, PMID 32961713.
19. Deng F, He S, Cui S, Shi Y, Tan Y, Li Z, *et al.* A molecular targeted immunotherapeutic strategy for ulcerative colitis via dual-targeting nanoparticles delivering miR-146b to intestinal macrophages. *J Crohns Colitis.* 2019;13(4):482-94. doi: 10.1093/ecco-jcc/jjy181, PMID 30445446.
20. Gugulothu D, Kulkarni A, Patravale V, Dandekar P. pH-sensitive nanoparticles of curcumin-celecoxib combination: evaluating drug synergy in ulcerative colitis model. *J Pharm Sci.* 2014;103(2):687-96. doi: 10.1002/jps.23828, PMID 24375287.
21. Li X, Lu C, Yang Y, Yu C, Rao Y. Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease. *Biomed Pharmacother.* 2020;129:110486. doi: 10.1016/j.biopha.2020.110486, PMID 32768972.
22. Yang C, Merlin D. Nanoparticle-mediated drug delivery systems for the treatment of IBD: current perspectives. *Int J Nanomedicine.* 2019;14:8875-89. doi: 10.2147/IJN.S210315, PMID 32009785.
23. Nedelcu A, Mosteanu O, Pop T, Mocan T, Mocan L. Recent advances in nanoparticle-mediated treatment of inflammatory bowel diseases. *Appl Sci.* 2021;11(1):438. doi: 10.3390/app11010438.
24. Naeem M, Bae J, Oshi MA, Kim MS, Moon HR, Lee BL, *et al.* Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis. *Int J Nanomedicine.* 2018;13:1225-40. doi: 10.2147/IJN.S157566, PMID 29535519.
25. Karlsson J, Vaughan HJ, Green JJ. Biodegradable polymeric nanoparticles for therapeutic cancer treatments. *Annu Rev Chem Biomol Eng.* 2018;9(1):105-27. doi: 10.1146/annurev-chembioeng-060817-084055, PMID 29579402.
26. Mallakpour S, Iderli M. Preparation of New Polymer nanocomposites Based on Chiral poly(amide-imide)/surface-modified ZnO Nanoparticles Containing 4,4'-methylene bis(3-chloro-2,6-diethylaniline) Linkages via ultrasonication-assisted Process. *Polym Bull.* 2013;70(7):2137-49. doi: 10.1007/s00289-013-0946-8.
27. Nasir A, Kausar A, Younus AA. A Review on preparation, properties and applications of polymeric nanoparticle-based materials. *Polym Plast Technol Eng.* 2015;54(4):325-41. doi: 10.1080/03602559.2014.958780.
28. Qin J, Liang G, Feng Y, Feng B, Wang G, Wu N, *et al.* Synthesis of gadolinium/iron-bimetal-phenolic coordination polymer nanoparticles for theranostic applications. *Nanoscale.* 2020;12(10):6096-103. doi: 10.1039/c9nr10020b, PMID 32129393.
29. Wang X, Hall JE, Warren S, Krom J, Magistrelli JM, Rackaitis M, *et al.* Synthesis, characterization, and application of novel polymeric nanoparticles. *Macromolecules.* 2007;40(3):499-508. doi: 10.1021/ma0613739.
30. Wang Y, Dave RN, Pfeffer R. Polymer coating/encapsulation of nanoparticles using a supercritical anti-solvent process. *J Supercrit Fluids.* 2004;28(1):85-99. doi: 10.1016/S0896-8446(03)00011-1.
31. Zhu W, Wu Y, Yan C, Wang C, Zhang M, Wu Z. Facile Synthesis of mono-dispersed polystyrene (Ps)/ag composite microspheres via modified chemical reduction. *Materials (Basel).* 2013;6(12):5625-38. doi: 10.3390/ma6125625, PMID 28788413.
32. Schädler LS, Kumar SK, Benicewicz BC, Lewis SL, Harton SE. Designed interfaces in polymer nanocomposites: A fundamental viewpoint. *MRS Bull.* 2007;32(4):335-40. doi: 10.1557/mrs2007.232.
33. Chen TY, Somasundaran P. Preparation of novel core-shell nanocomposite particles by controlled polymer bridging. *J Am Ceram Soc.* 1998;81(1):140-4. doi: 10.1111/j.1151-2916.1998.tb02305.x.
34. Shi D, He P, Lian J, Wang L, van Ooij WJ. Plasma deposition and characterization of acrylic acid thin film on ZnO nanoparticles. *J Mater Res.* 2002;17(10):2555-60. doi: 10.1557/JMR.2002.0371.
35. Ding L, Liu Z, Aggrey MO, Li C, Chen J, Tong L. Nanotoxicity: the toxicity research progress of metal and metal-containing nanoparticles. *Mini Rev Med Chem.* 2015;15(7):529-42. doi: 10.2174/138955751507150424104334, PMID 25934980.
36. Chen GH, Wu DJ, Weng WG, Yan WL. Preparation of polymer/graphite conducting nanocomposite by intercalation polymerization. *J Appl Polym Sci.* 2001;82(10):2506-13. doi: 10.1002/app.2101.
37. Mikitaev AK, Kaladzhyan AA, Lednev OB, Mikitaev MA, Davydov EM. Nanocomposite polymer materials on basis of organoclays with increased fire resistance; 2005. p. 36-43.
38. Nakayama N, Hayashi T. Preparation and characterization of TiO₂ and polymer nanocomposite films with high refractive index. *J Appl Polym Sci.* 2007;105(6):3662-72. doi: 10.1002/app.26451.
39. Ganguly D, Choudhury A, Majumdar S. Nanotechnology approaches for colon targeted drug delivery system: a review. *J Young Pharm.* 2023;15(2):233-8. doi: 10.5530/jyp.2023.15.32.
40. Raval AG, Bharadia PD, Modi D, Pandya V. Nanotechnology: A targeted drug delivery system for cancer therapy. *J Pharm Cosmetol.* 2011;1(5):67-75.

Cite this article: Ganguly D, Chanda R, Sardar D, Das H, Mitra S, Ghosh R, *et al.* Nanoparticulate Formulation for the Treatment of Different Types of Colon Disease Like Ulcerative Colitis: A Comprehensive Review. *J Young Pharm.* 2023;15(4):585-8.